3DBioFibR manufactures biopolymer fibers for medical, defense, and textile applications using patented dry-spinning tech.
Abacus develops therapeutic vaccines to treat cancer and chronic viral infections that cause cancer.
Operator of a material science company producing renewable, biodegradable plastics from algae for applications like footwear and surfboards.
Ampd is the fastest, simplest, and most powerful way to launch and maximize Google Ads to marketplaces such as Amazon or Walmart.
Anuncia develops CSF Management/Neurocritical Care therapeutic & monitoring devices for noninvasive at-home use.
Aurenar is improving stroke outcomes and reducing hospital stays/costs with an easy-to-use non-invasive ear stimulation device that activates the body's naturally healing vagal nerve response--with validated clinical results from a recent randomized controlled clinical study.
CorRen is eliminating preventable amputations by bringing reimbursed, specialist-grade PAD testing to primary care.
Cyrus Biotechnology is a pre-clinical-stage AI-driven therapeutics company with an internal pipeline of novel biologics primarily in autoimmune indications.
Ecellix has developed silicon anodes that empower battery makers to shatter limits: high energy, low cost & long life.
Enosemi's semiconductor designs will power the next generation of photonic products for connectivity, computing, sensing, mixed reality, medtech, biotech, and beyond. Note: Enosemi had a successful exit in mid 2025, producing a return for both IF2 and IF4.
Our vision is to build an environment of technology to serve the airport of the future with the goal of increasing safety, efficiency, and to capture service revenue on 100M+ movements at airports each year.
Fitnescity is a consumer health platform that provides easy access to tests and personalized analytics.
Glidance is developing Glide, a personal robot to help blind individuals navigate independently using AI and robotics.
Healionics provides safer, more reliable means of bloodstream access for dialysis in patients with kidney failure.
To become the first line on the table therapy in treating peripheral vascular occlusions by developing a solution aimed at rapid reperfusion without the need for surgery or thrombolytic drug therapies.
Indicio provides interoperable verifiable credential software to global enterprises for integration in existing systems.